Dr. Reddy’s Laboratories has announced that Immutep‘s Independent Data Monitoring Committee recommended halting the TACTI-004 Phase III trial of Eftilagimod Alfa for non-small cell lung cancer. This decision follows an interim futility analysis.
The trial’s discontinuation was advised after reviewing safety and efficacy data, leading to the suspension of patient enrolment and an orderly wind-down of the study. Immutep will conduct a comprehensive review of the data to understand the results better and decide on future steps for the programme.
Dr. Reddy’s Laboratories SA, a subsidiary of Dr. Reddy’s Laboratories, had previously made an upfront payment to Immutep as part of their strategic collaboration. The company continues to engage with Immutep to determine the appropriate way forward. Immutep remains committed to advancing its pipeline of innovative therapies, including Eftilagimod Alfa.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).